Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P1.04-008 - POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
09:30 - 09:30 | Presenter: Tony SK Mok | Author(s): M.L. Johnson, Edward Brian Garon, Solange Peters, J. Soria, L. Wang, A. Jarkowski, P.A. Dennis, Caicun Zhou
- Abstract
Loading...
-
+
PL 02 - Presidential Symposium including Top 3 Abstracts and James Cox Lectureship Award Presentation
- 08:15 - 09:45
- 10/17/2017
- Location: Plenary Hall (Exhibit Hall D)
- Type: Plenary Session
- Track: Early Stage NSCLC
- Moderators:Hisao Asamura, Keunchil Park
-
+
PL 02.02 - Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC
08:20 - 08:30 | Presenter: R. Hui | Author(s): M. Özgüroğlu, D. Daniel, D.V. Baz, S. Murakami, T. Yokoi, A. Chiappori, K.H. Lee, M. De Wit, B. Chul Cho, J.E. Gray, A. Rydén, L. Viviers, L. Poole, P.A. Dennis, S.J. Antonia
- Abstract
Loading...
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P2.04-001 - BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC
09:30 - 09:30 | Presenter: Ihor Vynnychenko | Author(s): H. Jiang, Y. Huang, P.A. Dennis, J. Von Pawel
- Abstract
Loading... -
+
P2.04-002 - CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
09:30 - 09:30 | Presenter: Luis Paz-Ares | Author(s): H. Jiang, Y. Huang, P.A. Dennis
- Abstract
Loading...